Dr. Grey AI

Plitidepsin (Aplidin)

Peptide

Plitidepsin is a cyclic depsipeptide originally from Mediterranean marine tunicate Aplidium albicans, now synthesized. FDA/EMA orphan drug status for multiple myeloma. Approved in Australia (2018) for relapsed/refractory MM. Phase III trials ongoing for breast and lung cancers. Targets eEF1A2 protein overexpressed in cancer. Phase I/II: Demonstrated antitumor activity with tolerable safety. Enhanced efficacy with dexamethasone combination. Safe cardiac profile (1.9% drug-related cardiac AEs in 578 patients). Also studied for COVID-19.

Quick Answer

What it is

Plitidepsin is a cyclic depsipeptide originally from Mediterranean marine tunicate Aplidium albicans, now synthesized. FDA/EMA orphan drug status for multiple myeloma.

Key findings

  • Grade A: Cardiac Safety Profile
  • Grade B: Anti-Cancer Activity
  • Grade B: Multiple Myeloma (with Dexamethasone)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Plitidepsin (Aplidin)

Quick Facts: Plitidepsin (Aplidin)

  • Best Evidence:Grade C
  • Conditions Studied:2
  • Research Outcomes:13
  • Grade A Findings:1
  • Grade B Findings:2
  • Key Effect:Respiratory Health
A1
B2
C7
D3
2 conditions · 13 outcomes

Detailed Outcomes

|
A
Cardiac Safety Profile
Comprehensive analysis (n=578): Only 1.9% drug-related cardiac AEs. No fatal cardiac events. Atrial fibrillation most common (2.6%). No life-threatening ventricular arrhythmias. Safe cardiac profile confirmed.
moderate↑Improves
B
Multiple Myeloma (with Dexamethasone)
Approved in Australia (2018) for relapsed/refractory MM. Enhanced activity with dexamethasone addition. Phase III trial comparing plitidepsin+dex vs dex alone. Orphan drug status in US and EU.
moderate↑Improves
C
Solid Tumor Response
Phase I/II trials: Limited single-agent activity in solid tumors (melanoma, breast, lung). Phase III ongoing for breast and lung cancers. Better activity expected in combination regimens.
small↑Improves
C
T-Cell Lymphoma
Phase II: Evaluated in noncutaneous peripheral T-cell lymphoma. Limited single-agent activity. Tolerable safety profile. Combination strategies being explored.
small↑Improves
B
Anti-Cancer Activity
33 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Antimicrobial Activity
6 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Cancer Cell Apoptosis
3 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Pulmonary Function
3 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Kidney Function
3 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Safety/Tolerability
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Liver Protection
2 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Immune Function
2 human trials support this finding. Human clinical trial data available.
small↑Improves
C
COVID-19 Antiviral Activity
In vitro and animal models: Significant reductions in SARS-CoV-2 viral load and pulmonary inflammation. Mechanism via eEF1A2 inhibition blocking viral replication. Clinical trials for COVID-19 application.
moderate↑Improves

Related Peptides

Tyrothricin

Peptide

1 shared condition · 6 outcomes

Tyrothricin is a cyclic peptide antibiotic complex from Bacillus brevis - the first peptide antibiotic used in humans (1939). Contains 60-80% tyrocidine (cyclic decapeptides) and 20-40% gramicidin (linear peptides). Over 60 years of clinical use with no significant resistance reported. RCT (DoriPha, n=321): Tyrothricin lozenges showed 64% improved complete remission vs placebo at 72 hours for acute pharyngitis. Used topically for sore throat, skin infections. SAFETY CONCERN: Systemic toxicity limits to topical/local use only.

Gramicidin

Peptide

1 shared condition · 8 outcomes

Gramicidin is a cyclic peptide antibiotic from Bacillus brevis, first isolated 1941, FDA-approved 1955 as Neosporin component. Topical use only (lozenges, eye drops, ointments) due to hemolysis. Gramicidin D (mixture of A/B/C) used clinically. Ophthalmic study (n=91): Effective and safe for bacterial corneal ulceration. Combined with polymyxin B and neomycin. One of first membrane-active peptide antibiotics. SAFETY CONCERN: Highly hemolytic - systemic use contraindicated.